FEB 10, 2015 9:00 AM PST

Primary HPV Cervical Cancer Screening: Supporting data and guidance updates

Speaker

Abstract
Date: Tuesday, February 10th, 2015
Time: 9:00AM PST, 12:00PM EST

For the last 60 years the primary method of preventing cervical cancer in both the U.S. and Europe has been cervical cytology -- if it is negative, women are rescreen in three years and if positive, are referred to follow-up examinations. Although this strategy has led to a tremendous reduction in the incidence of cervical cancer, some significant limitations exist. Cytology has low sensitivity for cervical cancer pre-cursors, has low reproducibility, and does not adequately assess long-term risk. HPV testing added to cytology as a co-test for women 30 years and older increases the sensitivity of cytology and addresses many of its limitation, but also significantly contributes to the complexity of management. In 2014, the FDA approved the first hrHPV test for the use as a primary test for cervical cancer screening for women 25 years and older. More recently, interim guidance was co-published by the Society of Gynecologic Oncology (SGO) and the American Society for Colposcopy and Cervical Pathology (ASCCP) on the use of primary hrHPV testing as an alternative to current US cytology-based cervical screening methods as it was found to provide greater reassurance of low CIN3+ risk than a negative cytology result. Additionally, due to the high prevalence of CIN3+ in women 25-29, for which cytology - the current standard of care - detected fewer than 50% of these cases, primary HPV testing could be imitated as early as age 25. Primary hrHPV screening is a significant scientific and clinical advance in cervical cancer screening as it provides improved reassurance of cancer risk following a negative result than cytology-based screening.

Learning objectives:
• Define HPV primary screening.
• Discuss key data around HPV primary screening.
• Describe new HPV primary screening and management guidance.

Show Resources
You May Also Like
NOV 16, 2022 7:00 PM PST
C.E. CREDITS
NOV 16, 2022 7:00 PM PST
Date: November 16, 2022 Time: 2:00pm (AEST) Date: November 17, 2022 7:00pm (PST), 10:00pm (EST), 4:00am (CET) The growth in FDA-approved cell and gene therapy products for the treatment of d...
FEB 15, 2023 7:00 AM PST
FEB 15, 2023 7:00 AM PST
Date: February 15, 2023 Time: 7:00am (PST), 10:00pm (EST), 4:00pm (CET) While not all microscopy samples can fluoresce, all can scatter light, and this scattered light can be imaged. This ha...
AUG 17, 2022 10:00 AM PDT
AUG 17, 2022 10:00 AM PDT
DATE: August 17, 2022 TIME: 10:00am PDT, 1:00pm EDT Detection and/or amplification of target DNA sequences by polymerase chain reaction (PCR) is a prevalent method in molecular biology. PCR...
SEP 29, 2022 11:00 AM PDT
SEP 29, 2022 11:00 AM PDT
Date: September 29, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEST) Pharmacogenomic (PGx) testing is a dynamic and fascinating application for genetic testing. We'll review the bas...
SEP 29, 2022 8:00 AM PDT
SEP 29, 2022 8:00 AM PDT
Date: September 29, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Adeno-associated virus (AAV) is one of the most widely used delivery vehicles in gene therapy. To ensure the safety...
OCT 13, 2022 9:00 AM +08
OCT 13, 2022 9:00 AM +08
First Broadcast: Date: October 12, 2022 Time: 8:00am PDT, 11:00am EDT Second Broadcast: Date: October 12, 2022 Time: 9:00am SGT The new Embedded CryoSPARC Live, now fully integrated with t...
Loading Comments...
Show Resources